Since March 2016, new direct-acting antiviral agents (DAAs) for treating infection with hepatitis C virus (HCV) have been available in Australia under the Pharmaceutical Benefits Scheme (PBS). This represents a revolution in the treatment of hepatitis C, as DAA regimens have cure rates of more than 90%, minimal adverse effects, and low treatment complexity. In contrast to previous HCV treatments, general practitioners are authorised to prescribe HCV DAAs. The Fourth National HCV Strategy emphasises that, to maximise the impact of HCV DAAs, most HCV treatment will need to move from hospital-based clinics to the primary care setting.1
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Australian Government Department of Health. Fourth national hepatitis C strategy 2014–2017. Canberra: The Commonwealth of Australia, 2014. http://www.health.gov.au/internet/main/publishing.nsf/content/ohp-bbvs-hepc (accessed Nov 2016).
- 2. Hajarizadeh B, Grebely J, McManus H, et al. Chronic hepatitis C burden and care cascade in Australia in the era of interferon-based treatment. J Gastroenterol Hepatol 2017; 32: 229-236.
- 3. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia. Annual surveillance report 2015. Sydney: The Kirby Institute, 2015. http://kirby.unsw.edu.au/surveillance/2015-annual-surveillance-report-hiv-viral-hepatitis-stis (accessed Oct 2016).
- 4. The Burnet Institute. Hepatitis C elimination. 2016. https://www.burnet.edu.au/system/asset/file/2270/Eliminate_Hep_C_Strategy_2016-web.pdf (accessed Oct 2016).
- 5. Morgan S, Magin PJ, Henderson KM, et al. Study protocol: the Registrar Clinical Encounters in Training (ReCEnT) study. BMC Fam Pract 2012; 13: 50.
- 6. Hays RB, Morgan S. Australian and overseas models of general practice training. Med J Aust 2011; 194: S63-S66. <MJA full text>
- 7. Hepatitis C Virus Infection Consensus Statement Working Group. Australian recommendations for the management of hepatitis C virus infection: a consensus statement 2016. Melbourne: Gastroenterological Society of Australia, 2016. https://www.asid.net.au/documents/item/1208 (accessed Feb 2017).
Joshua Davis has previously received research funding from Gilead Sciences and Abbvie for viral hepatitis-related research, but not for the study reported in this article.